Scancell (LON:SCLP) Trading 20.2% Higher – Should You Buy?

Scancell Holdings plc (LON:SCLP)’s stock price rose 20.2% during trading on Monday . The company traded as high as GBX 11 ($0.14) and last traded at GBX 10.19 ($0.13). Approximately 1,738,488 shares were traded during trading, an increase of 124% from the average daily volume of 777,450 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Stock Up 20.2 %

The company’s 50-day simple moving average is GBX 8.43 and its two-hundred day simple moving average is GBX 10.88. The firm has a market cap of £105.54 million, a PE ratio of -15.62 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.

Scancell (LON:SCLP) last posted its earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. On average, analysts predict that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.